

Availability of the vaccines for food producing aquatic animals in the E.U. and associated countries

Prof. Dr Dušan Palić

Chair for Fish Diseases and Fisheries Biology, LMU Munich

Director For Europe, World Aquatic Veterinary Medical Association

AAC meeting, 08.06.2026

There are several (16) commercial antibacterial vaccines registered in EU MS/AS for fish (Rathor & Swain, 2024)

Disease	Pathogen	Host	Type of Vaccine	Route of Delivery	Trade Name	Country
Furunculosis	Aeromonas salmonicida	Atlantic salmon and rainbow trout	Inactivated, oil-based	IP	AlphaJect 3000	Denmark, Finland, Iceland, Ireland, Norway, Sweden
					Alpha Ject® 2.2	UK
					Alpha Ject® 6-2	Norway, The Faroe Islands
			Subunit vaccine Inactivated bacterin	IP	Alpha Ject® micro 7 ILA	Norway, The Faroe Islands
				IP	Norvax® Minova 6	Norway
Streptococcus is	Streptococcus parauberis	turbot	Inactivated	IP	Ichthiovac-STR	Spain
Vibriosis	V. anguillarum V. ordalii	Atlantic salmon	Inactivated, oil-based	IP	Alpha Ject® micro 7 ILA, Alpha Ject® 6-2	Norway, The Faroe Islands
			Subunit vaccine	IP	Norvax® Minova 6	Norway
			Inactivated, oil-based	IP	Alpha Ject® micro 6	Ireland, UK, The Faroe Islands, Norway
		sea bass	Inactivated, oil-based	IP	Alpha Ject® micro 2000	Croatia, Spain, Greece, France
		Atlantic salmon and rainbow trout	Inactivated, oil-based	IP	Alpha Ject® 5-3	Iceland, Norway
		Atlantic salmon and rainbow trout	Inactivated, oil-based	IP	AlphaJect 3000	Denmark, Finland, Iceland, Ireland, Norway, Sweden
		Sea bass	Inactivated, oil-based	Dip	ALPHA DIP® Vib	Croatia, Cyprus, Greece, Italy, Portugal Spain
		Sea bass	Inactivated, oil-based	Bath/ Immersion	ALPHA DIP® Vibrio	Turkey
		European sea bass	Inactivated bacterin	IP	AquaVac Vibrio Pasteurella	Greece
		rainbow trout	Inactivated bacterin	Oral/ Immersion	AquaVac Vibrio, AquaVac Vibrio Oral Boost	Finland, UK, Ireland, Spain, Greece

There are several (11) commercial antiviral vaccines registered in EU MS/AS for fish (Rathor & Swain, 2024)

Virus	Type of Virus (RNA/DNA)	Fish Host	Trade Name (If Applicable)	Type of Vaccine	Delivery Method	Licensed for Use in the Following Countries	Description
SAV	RNA	Atlantic salmon	Norvax Compact PD	Inactivated	Intraperitoneal Injection	Norway Chile UK	A monovalent vaccine which contains an inactivated strain of SAV subtype 1.
SAV	RNA	Atlantic salmon	Aquavac PD7	Inactivated	Intraperitoneal Injection	Norway	A polyvalent vaccine which contains seven strains to protect against pancreatic disease, infectious pancreatic necrosis, furunculosis, cold-water vibriosis, vibriosis and winter ulcers. Specifically, to protect against SAV, it contains an inactivated strain of SAV subtype 1.
SAV	RNA	Atlantic salmon	Aquavac PD3	Inactivated	Intraperitoneal Injection	UK	A polyvalent vaccine which contains an inactivated strain of SAV subtype 1, as well as infectious pancreatic necrosis and furunculosis.
SAV	RNA	Atlantic salmon	Alphaject Micro 1 PD	Inactivated	Intraperitoneal Injection	UK Norway	A monovalent vaccine which contains the inactivated SAV subtype 3, the SAV strain most dominant in Norway.
IPNV	RNA	Atlantic salmon, rainbow trout	AlphaJect 1000	Inactivated	Intraperitoneal Injection	Chile Norway UK	A monovalent vaccine containing an inactivated form of the virus.
IPNV	RNA	Atlantic salmon	AlphaJect 2-2	Inactivated	Intraperitoneal Injection	UK	A bivalent vaccine protecting against IPNV and Furunculosis.
IPNV	RNA	Atlantic salmon	Pentium Forte Plus	Inactivated	Intraperitoneal Injection	Norway	Contains inactivated whole virus of IPNV, and also protects against Furunculosis, Classical Vibriosis, coldwater vibriosis, and Winter Ulcer.
IPNV	RNA	Atlantic Salmon	Norvax Minova 6	Subunit, inactivated	Intraperitoneal Injection	UK Norway	A multivalent vaccine which protects against Furunculosis, classical vibriosis, coldwater vibriosis, wound disease and IPNV. It contains a subunit VP2 capsid protein.
IPNV	RNA	Atlantic salmon	AlphaJect Micro 6	Inactivated	Intraperitoneal Injection	Norway United Kingdom The Faroe Islands Ireland	A multivalent vaccine protecting against Furunculosis, Vibriosis, cold-water vibriosis, Winter sore, and IPNV.
IPNV	RNA	Atlantic Salmon	AlphaJect 6-2	Inactivated	Intraperitoneal Injection	Norway The Faroe Islands	A polyvalent vaccine protecting against Furunculosis, Vibriosis. Coldwater vibriosis, Winter sore, and IPNV.
IPNV and ISA	RNA	Atlantic salmon	AlphaJect Micro 7	Inactivated	Intraperitoneal Injection	Norway The Faroe Islands	A multivalent vaccine protecting against, Furunculosis, Vibriosis, Coldwater vibriosis, Winter sore, IPNV, and (ISA).

The Paradox of Availability: A Review of the Evolution of VMPs for Aquaculture in Europe (2018–2026) Note: **vaccines**

Species	Total Authorized VMPs 2026	Total Authorized and Available VMPs 2026	Total Authorized, Available and Distinct VMPs (with unique active substances) 2026	Number of VMPs with new active substances newly authorized and available between 2018 and 2026
Atlantic Salmon (including Salmonid)	47	27	20 (Multiple vaccines ; Deltamethrin; Isoeugenol; Imidacloprid; Benzocaine; Oxytetracycline; TMPS; Tricaine mesylate; Bronopol; Azamethiphos; Emamectin benzoate)	3 (2 new vaccines available ; Imidacloprid)
Sea Bass	17	8	5 (4 Vaccines and Oxytetracycline)	0
Sea Bream	6	2	1 (2 oxytetracycline products are authorized and available under 2 different companies)	0
Trout (including Salmonid)	56	25	14 (2 vaccines ; Deltamethrin; Florfenicol; Isoeugenol; Benzocaine; Imidacloprid; Oxytetracycline; TMPS; Tricaine mesylate; Flumequine; Bronopol; Buserelin; Emamectin benzoate)	1 (Imidacloprid)
Carp	17	6	2 (Oxytetracycline; Florfenicol)	0
Any products for 'Fish' / 'Other Fish' / Fish (fresh water) which were not already included in species-specific numbers above	49	15	8 (oxytetracycline; florfenicol; chlortetracycline; flumequine; enrofloxacin; oxolinic acid; tricaine mesylate; TMPS)	0

Who will make the needed vaccines?

Metric	2018: Number of Companies with Authorized Products	2026: Number of Companies with Authorized Products	2026: Number of Companies with Available Products	Change (2018 compared to 2026 in number of unique companies and continuing vs left)
Total unique companies	47	40	19	-7
Companies continuing		21		46.8% of 2018
Companies that left	26			55.3% of 2018
New companies		19		45% of 2026

Solutions?

- Commercial vaccine incentives?
- Cascade “use of a product in accordance with Article 114 is focused in particular on avoiding unacceptable suffering to the treated animal”
- Autogenous vaccines?

Open discussion